Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald's (MCD) Tops Q4 EPS by 3c
- Procter & Gamble (PG) PT Raised to $96 at UBS Following 2Q Report
- Preferred Bank (PFBC) PT Raised to $65 at FBR Capital Following 4Q EPS Beat
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!